IMR Press / FBL / Volume 16 / Issue 3 / DOI: 10.2741/3729

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Article
The neurobiology of APOE in schizophrenia and mood disorders
Show Less
1 Rebecca L Cooper Laboratories, Mental Health Research Institute of Victoria, Parkville, Victoria, Victoria 3052, Australia.
2 Department of Psychiatry, The University of Melbourne, Parkville, Victoria 3010, Australia
3 The Centre for Neuroscience, The University of Melbourne, Victoria Australia
4 Department of Anatomy and Cell Biology, The University of Melbourne, Parkville, Victoria 3010, Australia
5 Department of Neuroscience, The University of Nottingham, Nottingham, UK
6 Department of Psychological Medicine, Monash University, Clayton, Victoria 3800, Australia
Academic Editor:Elizabeth A. Thomas
Front. Biosci. (Landmark Ed) 2011, 16(3), 962–979;
Published: 1 January 2011

APOE is a major component of several lipoproteins. In addition to its role as a lipid transport protein APOE also serves a dual role as a glial derived, synaptic signalling molecule and thought to play an important role in synaptic plasticity and cognition. Polymorphisms within the APOE gene have been associated with the incidence of Alzheimer's disease. In light of the similarities in the cognitive deficits experienced in both Alzheimer's disease and schizophrenia as well as the comorbidity of depression in Alzheimer's disease, aberrant APOE signalling has been implicated in the pathologies of schizophrenia and mood disorders. The schizophrenia candidate gene, reelin, also shares common receptors with APOE, further supporting a role for APOE in the pathology of these disorders. This review will summarise the current understanding of the involvement of APOE and its receptors in the symptomatology and pathology of schizophrenia and mood disorders and the implications of this involvement for drug treatment.

Back to top